Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Saad F, O'Sullivan J, Federhofer J, Wirth M, Tucci M, Petrenciuc O, Nilsson S, Miller K, Lévy J, Gratt J, Heinrich D, Heidenreich A, Gillessen Sommer S, Carles J. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016; 17:1306-16.
Jul 26, 2016
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Jul 26, 2016
Lancet Oncol 2016; 17:1306-16
Saad Fred, O'Sullivan Joe M, Federhofer Judith, Wirth Manfred, Tucci Marcello, Petrenciuc Oana, Nilsson Sten, Miller Kurt, Lévy Jérémy, Gratt Jeremy, Heinrich Daniel, Heidenreich Axel, Gillessen Sommer Silke, Carles Joan
more
